A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- Progression free survival (PFS)
Study Overview
Brief Summary
The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.
The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib activity and establishing a cutoff value as potential selection criteria for phase III.
Other secondary objectives are to assess the tolerability and safety of lenvatinib in this setting and overall survival, response and disease control.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Female subjects age ≥18 years at the time of informed consent
- •World Health Organization (WHO) Performance Status of 0 or 1
- •Patients with histologically confirmed endometrial cancer including serous-papillary and clear cell histologies. Uterine carcinosarcomas are allowed.
- •Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment options exist.
- •Patients with disease progression following platinum-based chemotherapy administered as either adjuvant or neoadjuvant treatment are also eligible.
- •Patients may have received prior radiotherapy and / or adjuvant chemotherapy for early high-risk disease
- •Patients may not have received prior treatment with anthracyclines
- •Blood samples available for retrospective central assessment of Ang-2 level
- •Patients may have had prior therapy providing the following conditions are met:
- •Surgery and radiation therapy: wash-out period of 14 days and subjects must have recovered adequately from any toxicity and/or complications from radiotherapy and major surgery prior to starting therapy.
- •Systemic anti-tumor therapy or any investigational agent: wash-out period of 21 days (or 5 x half-life)
- •Recovery from any toxic effects of prior therapy to ≤ Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.) except alopecia
- •Adequate contraceptive measures
- •Signed written informed consent
Exclusion Criteria
- •Inadequate hematologic, renal and hepatic functions
- •Abnormal cardiac function
Arms & Interventions
Lenvatinib
Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
Intervention: Lenvatinib (Drug)
Doxorubicin
Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
Intervention: Doxorubicin (Drug)
Outcomes
Primary Outcomes
Progression free survival (PFS)
Time Frame: 2.5 years
PFS assessed by Response Evaluation Criteria in Solid Tumors (RECIST
Secondary Outcomes
No secondary outcomes reported